Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	microfilament motor activity	MYH1 MYH4 MYH11 MYO5A	4.71e-06	38	59	4	GO:0000146
GeneOntologyMolecularFunction	glycerol dehydrogenase (NADP+) activity	AKR1A1 AKR1B1	8.58e-06	2	59	2	GO:0047956
GeneOntologyMolecularFunction	L-glucuronate reductase activity	AKR1A1 AKR1B1	8.58e-06	2	59	2	GO:0047939
GeneOntologyMolecularFunction	glycerol dehydrogenase [NAD(P)+] activity	AKR1A1 AKR1B1	8.58e-06	2	59	2	GO:1990042
GeneOntologyMolecularFunction	cytoskeletal motor activity	MYH1 MYH4 MYH11 MYO5A DNAH17	2.57e-05	118	59	5	GO:0003774
GeneOntologyMolecularFunction	SUMO ligase activity	RGPD4 RANBP2 RGPD3	2.70e-05	20	59	3	GO:0061665
GeneOntologyMolecularFunction	small GTPase binding	RGPD4 DENND5B RANBP2 MYO5A AP1G1 RGPD3 OCRL	4.33e-05	321	59	7	GO:0031267
GeneOntologyMolecularFunction	allyl-alcohol dehydrogenase activity	AKR1A1 AKR1B1	5.13e-05	4	59	2	GO:0047655
GeneOntologyMolecularFunction	GTPase binding	RGPD4 DENND5B RANBP2 MYO5A AP1G1 RGPD3 OCRL	8.90e-05	360	59	7	GO:0051020
GeneOntologyMolecularFunction	SUMO transferase activity	RGPD4 RANBP2 RGPD3	1.63e-04	36	59	3	GO:0019789
GeneOntologyMolecularFunction	peptidyl-prolyl cis-trans isomerase activity	RGPD4 RANBP2 RGPD3	4.35e-04	50	59	3	GO:0003755
GeneOntologyMolecularFunction	cis-trans isomerase activity	RGPD4 RANBP2 RGPD3	5.17e-04	53	59	3	GO:0016859
GeneOntologyMolecularFunction	metal-dependent deubiquitinase activity	MPND MYSM1	5.56e-04	12	59	2	GO:0140492
GeneOntologyMolecularFunction	aldose reductase (NADPH) activity	AKR1A1 AKR1B1	7.63e-04	14	59	2	GO:0004032
GeneOntologyMolecularFunction	ubiquitin-ubiquitin ligase activity	UBE4A UBE4B	7.63e-04	14	59	2	GO:0034450
GeneOntologyMolecularFunction	ubiquitin-like protein ligase activity	RGPD4 UBE4A RANBP2 UBE4B RGPD3 NFX1	1.12e-03	398	59	6	GO:0061659
GeneOntologyMolecularFunction	GTPase activator activity	RGPD4 RANBP2 RANBP3L RGPD3 OCRL	1.39e-03	279	59	5	GO:0005096
GeneOntologyMolecularFunction	double-stranded RNA binding	MYH4 AGO3 SIDT1	1.59e-03	78	59	3	GO:0003725
GeneOntologyMolecularFunction	alcohol dehydrogenase (NADP+) activity	AKR1A1 AKR1B1	2.87e-03	27	59	2	GO:0008106
GeneOntologyMolecularFunction	nucleoside-triphosphatase regulator activity	RGPD4 DENND5B RANBP2 RANBP3L RGPD3 OCRL	3.75e-03	507	59	6	GO:0060589
GeneOntologyMolecularFunction	GTPase regulator activity	RGPD4 DENND5B RANBP2 RANBP3L RGPD3 OCRL	3.75e-03	507	59	6	GO:0030695
GeneOntologyMolecularFunction	ubiquitin-like protein transferase activity	RGPD4 UBE4A RANBP2 UBE4B RGPD3 NFX1	3.94e-03	512	59	6	GO:0019787
GeneOntologyMolecularFunction	aldo-keto reductase (NADPH) activity	AKR1A1 AKR1B1	4.02e-03	32	59	2	GO:0004033
GeneOntologyMolecularFunction	actin filament binding	MYH1 MYH4 MYH11 MYO5A	4.54e-03	227	59	4	GO:0051015
GeneOntologyMolecularFunction	aminoacyltransferase activity	RGPD4 UBE4A RANBP2 UBE4B RGPD3 NFX1	4.74e-03	532	59	6	GO:0016755
GeneOntologyMolecularFunction	calmodulin binding	MYH1 MYH4 MYH11 MYO5A	4.76e-03	230	59	4	GO:0005516
GeneOntologyBiologicalProcess	positive regulation of glucokinase activity	RGPD4 RANBP2 RGPD3	1.66e-06	9	57	3	GO:0033133
GeneOntologyBiologicalProcess	positive regulation of hexokinase activity	RGPD4 RANBP2 RGPD3	2.37e-06	10	57	3	GO:1903301
GeneOntologyBiologicalProcess	regulation of glucokinase activity	RGPD4 RANBP2 RGPD3	5.61e-06	13	57	3	GO:0033131
GeneOntologyBiologicalProcess	regulation of hexokinase activity	RGPD4 RANBP2 RGPD3	7.13e-06	14	57	3	GO:1903299
GeneOntologyBiologicalProcess	monosaccharide biosynthetic process	RGPD4 RANBP2 RGPD3 AKR1A1 AKR1B1	2.10e-05	121	57	5	GO:0046364
GeneOntologyBiologicalProcess	NLS-bearing protein import into nucleus	RGPD4 RANBP2 RGPD3	2.21e-05	20	57	3	GO:0006607
GeneOntologyBiologicalProcess	lactone biosynthetic process	AKR1A1 AKR1B1	7.46e-05	5	57	2	GO:1901336
GeneOntologyBiologicalProcess	L-ascorbic acid biosynthetic process	AKR1A1 AKR1B1	7.46e-05	5	57	2	GO:0019853
GeneOntologyBiologicalProcess	establishment of RNA localization	RGPD4 RANBP2 RGPD3 SIDT1 ATM	1.32e-04	178	57	5	GO:0051236
GeneOntologyBiologicalProcess	protein peptidyl-prolyl isomerization	RGPD4 RANBP2 RGPD3	1.58e-04	38	57	3	GO:0000413
GeneOntologyBiologicalProcess	monosaccharide metabolic process	RGPD4 RANBP2 RGPD3 AKR1A1 PPARD AKR1B1	2.09e-04	310	57	6	GO:0005996
GeneOntologyBiologicalProcess	daunorubicin metabolic process	AKR1A1 AKR1B1	2.67e-04	9	57	2	GO:0044597
GeneOntologyBiologicalProcess	hexose biosynthetic process	RGPD4 RANBP2 RGPD3 AKR1B1	2.88e-04	115	57	4	GO:0019319
GeneOntologyBiologicalProcess	RNA localization	RGPD4 RANBP2 RGPD3 SIDT1 ATM	3.30e-04	217	57	5	GO:0006403
GeneOntologyBiologicalProcess	doxorubicin metabolic process	AKR1A1 AKR1B1	3.33e-04	10	57	2	GO:0044598
GeneOntologyBiologicalProcess	polyketide metabolic process	AKR1A1 AKR1B1	3.33e-04	10	57	2	GO:0030638
GeneOntologyBiologicalProcess	aminoglycoside antibiotic metabolic process	AKR1A1 AKR1B1	3.33e-04	10	57	2	GO:0030647
GeneOntologyBiologicalProcess	pigmentation	MYO5A AP1G1 LYST MYSM1	3.96e-04	125	57	4	GO:0043473
GeneOntologyBiologicalProcess	axo-dendritic protein transport	MYO5A NETO1	4.06e-04	11	57	2	GO:0099640
GeneOntologyBiologicalProcess	elastic fiber assembly	MYH11 TNXB	4.06e-04	11	57	2	GO:0048251
GeneOntologyBiologicalProcess	peptidyl-proline modification	RGPD4 RANBP2 RGPD3	4.49e-04	54	57	3	GO:0018208
GeneOntologyBiologicalProcess	small molecule biosynthetic process	RGPD4 RANBP2 MYO5A RGPD3 AKR1A1 NDUFA9 AKR1B1 KYNU	5.11e-04	676	57	8	GO:0044283
GeneOntologyBiologicalProcess	carbohydrate biosynthetic process	RGPD4 RANBP2 RGPD3 AKR1A1 AKR1B1	5.96e-04	247	57	5	GO:0016051
GeneOntologyBiologicalProcess	male meiotic nuclear division	BRCA2 SGO2 ATM	6.12e-04	60	57	3	GO:0007140
GeneOntologyBiologicalProcess	water-soluble vitamin biosynthetic process	AKR1A1 AKR1B1	6.68e-04	14	57	2	GO:0042364
GeneOntologyCellularComponent	cytoplasmic periphery of the nuclear pore complex	RGPD4 RANBP2 RGPD3	1.18e-06	8	59	3	GO:1990723
GeneOntologyCellularComponent	nuclear pore cytoplasmic filaments	RGPD4 RANBP2 RGPD3	2.53e-06	10	59	3	GO:0044614
GeneOntologyCellularComponent	annulate lamellae	RGPD4 RANBP2 RGPD3	7.60e-06	14	59	3	GO:0005642
GeneOntologyCellularComponent	muscle myosin complex	MYH1 MYH4 MYH11	1.17e-05	16	59	3	GO:0005859
GeneOntologyCellularComponent	nuclear pore nuclear basket	RGPD4 RANBP2 RGPD3	1.69e-05	18	59	3	GO:0044615
GeneOntologyCellularComponent	myosin complex	MYH1 MYH4 MYH11 MYO5A	2.32e-05	59	59	4	GO:0016459
GeneOntologyCellularComponent	nuclear inclusion body	RGPD4 RANBP2 RGPD3	2.35e-05	20	59	3	GO:0042405
GeneOntologyCellularComponent	SUMO ligase complex	RGPD4 RANBP2 RGPD3	2.74e-05	21	59	3	GO:0106068
GeneOntologyCellularComponent	myosin filament	MYH1 MYH4 MYH11	4.70e-05	25	59	3	GO:0032982
GeneOntologyCellularComponent	myosin II complex	MYH1 MYH4 MYH11	6.65e-05	28	59	3	GO:0016460
GeneOntologyCellularComponent	nuclear pore	RGPD4 RANBP2 RANBP3L RGPD3	1.91e-04	101	59	4	GO:0005643
GeneOntologyCellularComponent	lateral element	BRCA2 RPA1	1.30e-03	19	59	2	GO:0000800
GeneOntologyCellularComponent	DNA repair complex	BRCA2 ATM	1.91e-03	23	59	2	GO:1990391
GeneOntologyCellularComponent	inclusion body	RGPD4 RANBP2 RGPD3	2.11e-03	90	59	3	GO:0016234
GeneOntologyCellularComponent	condensed nuclear chromosome	AGO3 BRCA2 RPA1	2.18e-03	91	59	3	GO:0000794
HumanPheno	Large clumps of pigment irregularly distributed along hair shaft	MYO5A LYST	6.36e-05	3	24	2	HP:0004527
HumanPheno	Melanin pigment aggregation in hair shafts	MYO5A LYST	1.27e-04	4	24	2	HP:0002220
HumanPheno	Abnormal iris pigmentation	MYH11 BRCA2 MYO5A UBE4B ATM OCRL RPA1 LYST	1.40e-04	355	24	8	HP:0008034
HumanPheno	Hypopigmentation of hair	BRCA2 MYO5A UBE4B ATM OCRL RPA1 LYST	1.98e-04	276	24	7	HP:0005599
HumanPheno	Ocular albinism	BRCA2 MYO5A UBE4B ATM OCRL RPA1 LYST	1.98e-04	276	24	7	HP:0001107
HumanPheno	Generalized hypopigmentation	BRCA2 MYO5A UBE4B ATM OCRL RPA1 LYST	1.98e-04	276	24	7	HP:0007513
HumanPheno	Albinism	BRCA2 MYO5A UBE4B ATM OCRL RPA1 LYST	1.98e-04	276	24	7	HP:0001022
HumanPheno	Hypopigmentation of the skin	BRCA2 MYO5A UBE4B ATM OCRL RPA1 LYST	1.98e-04	276	24	7	HP:0001010
HumanPheno	Abnormality of hair pigmentation	BRCA2 MYO5A UBE4B ATM OCRL RPA1 LYST	2.17e-04	280	24	7	HP:0009887
HumanPheno	Silver-gray hair	MYO5A LYST	3.15e-04	6	24	2	HP:0002218
HumanPheno	Accumulation of melanosomes in melanocytes	MYO5A LYST	3.15e-04	6	24	2	HP:0001008
HumanPheno	Iris hypopigmentation	BRCA2 MYO5A UBE4B ATM OCRL RPA1 LYST	3.19e-04	298	24	7	HP:0007730
MousePheno	decreased tumor latency	RGPD4 RANBP2 BRCA2 RGPD3	3.71e-06	30	50	4	MP:0010308
MousePheno	abnormal chromosome morphology	RGPD4 PDS5B RANBP2 BRCA2 RGPD3 ATM	5.47e-06	126	50	6	MP:0003702
MousePheno	abnormal mitosis	RGPD4 PDS5B RANBP2 BRCA2 RGPD3 PRIMPOL	5.99e-06	128	50	6	MP:0004046
MousePheno	abnormal tumor latency	RGPD4 RANBP2 BRCA2 RGPD3	6.21e-06	34	50	4	MP:0010307
MousePheno	elevated level of mitotic sister chromatid exchange	RGPD4 RANBP2 RGPD3	2.33e-05	16	50	3	MP:0003701
MousePheno	abnormal cell nucleus morphology	RGPD4 PDS5B RANBP2 BRCA2 RGPD3 ATM	4.71e-05	184	50	6	MP:0003111
MousePheno	aneuploidy	RGPD4 PDS5B RANBP2 RGPD3	6.50e-05	61	50	4	MP:0004024
MousePheno	increased carcinoma incidence	RGPD4 RANBP2 BRCA2 RGPD3 ATM PPARD	6.88e-05	197	50	6	MP:0002038
MousePheno	abnormal morula morphology	RGPD4 RANBP2 RGPD3	1.06e-04	26	50	3	MP:0012058
MousePheno	increased hepatocellular carcinoma incidence	RGPD4 RANBP2 RGPD3 ATM	1.12e-04	70	50	4	MP:0003331
MousePheno	abnormal foot pigmentation	MYO5A LYST MYSM1	1.32e-04	28	50	3	MP:0009379
MousePheno	failure of blastocyst formation	RGPD4 RANBP2 RGPD3	1.80e-04	31	50	3	MP:0012129
MousePheno	increased malignant tumor incidence	RGPD4 RANBP2 BRCA2 RGPD3 ATM PPARD	1.90e-04	237	50	6	MP:0002018
MousePheno	embryonic lethality before implantation	RGPD4 RANBP2 GTF3C1 AP1G1 RGPD3 RPA1	2.13e-04	242	50	6	MP:0006204
MousePheno	abnormal chromosome number	RGPD4 PDS5B RANBP2 RGPD3	2.48e-04	86	50	4	MP:0004023
MousePheno	abnormal thyroid follicular cell morphology	AP1G1 TG	2.60e-04	7	50	2	MP:0004697
MousePheno	abnormal vitamin C level	AKR1A1 AKR1B1	2.60e-04	7	50	2	MP:0011229
MousePheno	impaired glucose tolerance	RGPD4 UBE4A RANBP2 RGPD3 GRIK4 ATM PPARD ZNF251	2.75e-04	480	50	8	MP:0005293
MousePheno	abnormal tail pigmentation	MYO5A LYST MYSM1	3.59e-04	39	50	3	MP:0005174
MousePheno	abnormal blastocyst formation	RGPD4 RANBP2 RGPD3	3.59e-04	39	50	3	MP:0012128
MousePheno	increased incidence of induced tumors	RGPD4 RANBP2 RGPD3 PPARD LYST	3.70e-04	173	50	5	MP:0002021
MousePheno	abnormal incidence of induced tumors	RGPD4 RANBP2 BRCA2 RGPD3 PPARD LYST	3.75e-04	269	50	6	MP:0013151
MousePheno	increased classified tumor incidence	RGPD4 RANBP2 BRCA2 RGPD3 ATM PPARD RPA1	3.84e-04	381	50	7	MP:0010273
MousePheno	abnormal glucose tolerance	RGPD4 DENND5B UBE4A RANBP2 RGPD3 GRIK4 ATM PPARD ZNF251 TG	3.98e-04	787	50	10	MP:0005291
MousePheno	abnormal classified tumor incidence	RGPD4 RANBP2 BRCA2 RGPD3 ATM PPARD RPA1	4.03e-04	384	50	7	MP:0020188
MousePheno	muscle weakness	MYH1 MYH4 MTERF2 PPARD	4.09e-04	98	50	4	MP:0000747
MousePheno	abnormal tumor susceptibility	RGPD4 RANBP2 BRCA2 RGPD3 ATM PPARD RPA1 LYST TNXB	4.35e-04	650	50	9	MP:0002166
MousePheno	ovary degeneration	BRCA2 ATM	4.44e-04	9	50	2	MP:0013236
MousePheno	abnormal hair follicle melanin granule morphology	MYO5A LYST	4.44e-04	9	50	2	MP:0005072
MousePheno	abnormal cell cycle	RGPD4 PDS5B RANBP2 BRCA2 RGPD3 SGO2 ATM PRIMPOL	4.70e-04	520	50	8	MP:0003077
MousePheno	increased sarcoma incidence	RGPD4 RANBP2 RGPD3 ATM	4.76e-04	102	50	4	MP:0002032
MousePheno	increased organ/body region tumor incidence	RGPD4 RANBP2 BRCA2 RGPD3 ATM PPARD RPA1	4.77e-04	395	50	7	MP:0010274
MousePheno	abnormal organ/body region tumor incidence	RGPD4 RANBP2 BRCA2 RGPD3 ATM PPARD RPA1	5.22e-04	401	50	7	MP:0013152
MousePheno	increased tumor incidence	RGPD4 RANBP2 BRCA2 RGPD3 ATM PPARD RPA1 LYST	5.34e-04	530	50	8	MP:0002020
MousePheno	decreased lean body mass	ACE2 UBE4A AP1G1 GRIK4 PPARD MYSM1 TG	5.71e-04	407	50	7	MP:0003961
MousePheno	abnormal intracellular organelle morphology	RGPD4 PDS5B RANBP2 BRCA2 MTERF2 RGPD3 ATM LYST	6.49e-04	546	50	8	MP:0014239
MousePheno	increased hepatobiliary system tumor incidence	RGPD4 RANBP2 RGPD3 ATM	6.55e-04	111	50	4	MP:0010297
MousePheno	increased liver tumor incidence	RGPD4 RANBP2 RGPD3 ATM	6.55e-04	111	50	4	MP:0008019
MousePheno	embryonic lethality before implantation, complete penetrance	RGPD4 RANBP2 AP1G1 RGPD3 RPA1	7.66e-04	203	50	5	MP:0011094
MousePheno	abnormal lymph circulation	LYVE1 EFNB2	8.09e-04	12	50	2	MP:0003659
MousePheno	hypopigmentation	MYO5A LYST MYSM1	8.89e-04	53	50	3	MP:0005408
MousePheno	abnormal hair cycle	MYO5A LYST MYSM1	9.91e-04	55	50	3	MP:0000427
MousePheno	neoplasm	RGPD4 RANBP2 BRCA2 RGPD3 ATM PPARD RPA1 LYST TNXB	1.18e-03	747	50	9	MP:0002006
MousePheno	abnormal urine amino acid level	MYH1 AKR1A1 AKR1B1	1.22e-03	59	50	3	MP:0011468
MousePheno	abnormal hair follicle melanocyte morphology	MYO5A LYST	1.28e-03	15	50	2	MP:0004381
Domain	Ran_BP1	RGPD4 RANBP2 RANBP3L RGPD3	3.79e-08	12	57	4	PF00638
Domain	RANBD1	RGPD4 RANBP2 RANBP3L RGPD3	3.79e-08	12	57	4	PS50196
Domain	RanBD	RGPD4 RANBP2 RANBP3L RGPD3	5.46e-08	13	57	4	SM00160
Domain	Ran_bind_dom	RGPD4 RANBP2 RANBP3L RGPD3	5.46e-08	13	57	4	IPR000156
Domain	Myosin_head_motor_dom	MYH1 MYH4 MYH11 MYO5A	5.33e-06	38	57	4	IPR001609
Domain	MYOSIN_MOTOR	MYH1 MYH4 MYH11 MYO5A	5.33e-06	38	57	4	PS51456
Domain	Myosin_head	MYH1 MYH4 MYH11 MYO5A	5.33e-06	38	57	4	PF00063
Domain	MYSc	MYH1 MYH4 MYH11 MYO5A	5.33e-06	38	57	4	SM00242
Domain	Ufd2P_core	UBE4A UBE4B	9.15e-06	2	57	2	PF10408
Domain	Ub_conjug_fac_E4_core	UBE4A UBE4B	9.15e-06	2	57	2	IPR019474
Domain	Myosin_N	MYH1 MYH4 MYH11	1.19e-05	15	57	3	PF02736
Domain	Myosin_N	MYH1 MYH4 MYH11	1.19e-05	15	57	3	IPR004009
Domain	Myosin_tail_1	MYH1 MYH4 MYH11	2.13e-05	18	57	3	PF01576
Domain	Myosin_tail	MYH1 MYH4 MYH11	2.13e-05	18	57	3	IPR002928
Domain	Myosin-like_IQ_dom	MYH1 MYH4 MYH11	2.52e-05	19	57	3	IPR027401
Domain	-	MYH1 MYH4 MYH11	2.52e-05	19	57	3	4.10.270.10
Domain	IQ	MYH1 MYH4 MYH11 MYO5A	6.50e-05	71	57	4	PF00612
Domain	Myosin_S1_N	MYH11 MYO5A	9.10e-05	5	57	2	IPR008989
Domain	IQ	MYH1 MYH4 MYH11 MYO5A	1.09e-04	81	57	4	SM00015
Domain	IQ_motif_EF-hand-BS	MYH1 MYH4 MYH11 MYO5A	1.64e-04	90	57	4	IPR000048
Domain	IQ	MYH1 MYH4 MYH11 MYO5A	1.86e-04	93	57	4	PS50096
Domain	GCC2_Rab_bind	RGPD4 RGPD3	1.90e-04	7	57	2	IPR032023
Domain	U_BOX	UBE4A UBE4B	1.90e-04	7	57	2	PS51698
Domain	Rab_bind	RGPD4 RGPD3	1.90e-04	7	57	2	PF16704
Domain	Ubox	UBE4A UBE4B	2.53e-04	8	57	2	SM00504
Domain	U-box	UBE4A UBE4B	2.53e-04	8	57	2	PF04564
Domain	ALDOKETO_REDUCTASE_1	AKR1A1 AKR1B1	4.05e-04	10	57	2	PS00798
Domain	Ubox_domain	UBE4A UBE4B	4.05e-04	10	57	2	IPR003613
Domain	Aldo/ket_reductase_CS	AKR1A1 AKR1B1	4.05e-04	10	57	2	IPR018170
Domain	Aldo/keto_reductase	AKR1A1 AKR1B1	4.05e-04	10	57	2	IPR020471
Domain	ALDOKETO_REDUCTASE_2	AKR1A1 AKR1B1	4.05e-04	10	57	2	PS00062
Domain	ALDOKETO_REDUCTASE_3	AKR1A1 AKR1B1	4.05e-04	10	57	2	PS00063
Domain	-	RGPD4 RGPD3	4.05e-04	10	57	2	1.10.220.60
Domain	Grip	RGPD4 RGPD3	4.94e-04	11	57	2	SM00755
Domain	GRIP	RGPD4 RGPD3	4.94e-04	11	57	2	PF01465
Domain	JAB_MPN	MPND MYSM1	5.92e-04	12	57	2	SM00232
Domain	GRIP_dom	RGPD4 RGPD3	5.92e-04	12	57	2	IPR000237
Domain	GRIP	RGPD4 RGPD3	5.92e-04	12	57	2	PS50913
Domain	JAMM/MPN+_dom	MPND MYSM1	5.92e-04	12	57	2	IPR000555
Domain	JAB	MPND MYSM1	5.92e-04	12	57	2	PF01398
Domain	-	EFNB2 F8	8.13e-04	14	57	2	2.60.40.420
Domain	-	AKR1A1 AKR1B1	1.07e-03	16	57	2	3.20.20.100
Domain	TPR-contain_dom	RGPD4 RANBP2 RGPD3 ZFC3H1	1.13e-03	150	57	4	IPR013026
Domain	NADP_OxRdtase_dom	AKR1A1 AKR1B1	1.21e-03	17	57	2	IPR023210
Domain	Aldo_ket_red	AKR1A1 AKR1B1	1.21e-03	17	57	2	PF00248
Domain	Aldo/ket_red/Kv-b	AKR1A1 AKR1B1	1.21e-03	17	57	2	IPR001395
Domain	TPR_REGION	RGPD4 RANBP2 RGPD3 ZFC3H1	1.61e-03	165	57	4	PS50293
Domain	TPR	RGPD4 RANBP2 RGPD3 ZFC3H1	1.61e-03	165	57	4	PS50005
Domain	FA58C	CNTNAP4 F8	1.85e-03	21	57	2	SM00231
Domain	FA58C_3	CNTNAP4 F8	1.85e-03	21	57	2	PS50022
Domain	FA58C_1	CNTNAP4 F8	1.85e-03	21	57	2	PS01285
Domain	FA58C_2	CNTNAP4 F8	1.85e-03	21	57	2	PS01286
Domain	Cupredoxin	EFNB2 F8	2.03e-03	22	57	2	IPR008972
Domain	F5_F8_type_C	CNTNAP4 F8	2.42e-03	24	57	2	PF00754
Domain	FA58C	CNTNAP4 F8	2.42e-03	24	57	2	IPR000421
Pathway	WP_HOMOLOGOUS_RECOMBINATION	BRCA2 ATM RPA1	6.55e-06	12	45	3	MM15951
Pathway	WP_HOMOLOGOUS_RECOMBINATION	BRCA2 ATM RPA1	8.50e-06	13	45	3	M39712
Pathway	REACTOME_GENE_SILENCING_BY_RNA	RGPD4 RANBP2 AGO3 RGPD3	1.73e-05	49	45	4	MM14837
Pathway	BIOCARTA_RANBP2_PATHWAY	RGPD4 RANBP2 RGPD3	2.40e-05	18	45	3	MM1549
Pathway	REACTOME_RESOLUTION_OF_SISTER_CHROMATID_COHESION	RGPD4 PDS5B RANBP2 RGPD3 SGO2	5.41e-05	129	45	5	MM14894
Pathway	REACTOME_REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE	RGPD4 RANBP2 RGPD3 RPA1	8.40e-05	73	45	4	MM14948
Pathway	REACTOME_SUMOYLATION_OF_DNA_DAMAGE_RESPONSE_AND_REPAIR_PROTEINS	RGPD4 RANBP2 RGPD3 RPA1	1.45e-04	84	45	4	MM14929
Pathway	REACTOME_CELLULAR_RESPONSE_TO_HEAT_STRESS	RGPD4 RANBP2 RGPD3 RPA1	2.06e-04	92	45	4	MM14951
Pathway	REACTOME_CELL_CYCLE_CHECKPOINTS	RGPD4 RANBP2 RGPD3 SGO2 ATM RPA1	2.07e-04	271	45	6	MM15388
Pathway	REACTOME_METABOLISM_OF_CARBOHYDRATES	RGPD4 LYVE1 RANBP2 RGPD3 AKR1A1 AKR1B1	2.07e-04	271	45	6	MM15406
Pathway	REACTOME_NUCLEAR_PORE_COMPLEX_NPC_DISASSEMBLY	RGPD4 RANBP2 RGPD3	2.77e-04	40	45	3	MM14945
Pathway	REACTOME_AMPLIFICATION_OF_SIGNAL_FROM_THE_KINETOCHORES	RGPD4 RANBP2 RGPD3 SGO2	2.84e-04	100	45	4	MM14561
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_SMALL_RNAS	RGPD4 RANBP2 RGPD3	2.98e-04	41	45	3	MM15200
Pathway	REACTOME_SUMOYLATION_OF_SUMOYLATION_PROTEINS	RGPD4 RANBP2 RGPD3	3.20e-04	42	45	3	MM15039
Pathway	REACTOME_HOMOLOGOUS_DNA_PAIRING_AND_STRAND_EXCHANGE	BRCA2 ATM RPA1	3.43e-04	43	45	3	M27588
Pathway	REACTOME_TRANSPORT_OF_THE_SLBP_DEPENDANT_MATURE_MRNA	RGPD4 RANBP2 RGPD3	3.43e-04	43	45	3	MM14609
Pathway	REACTOME_SEPARATION_OF_SISTER_CHROMATIDS	RGPD4 PDS5B RANBP2 RGPD3 SGO2	3.58e-04	193	45	5	MM14890
Pathway	REACTOME_MITOTIC_PROMETAPHASE	RGPD4 PDS5B RANBP2 RGPD3 SGO2	4.41e-04	202	45	5	MM15362
Pathway	PID_FANCONI_PATHWAY	BRCA2 ATM RPA1	4.47e-04	47	45	3	M1
Pathway	REACTOME_SUMOYLATION_OF_UBIQUITINYLATION_PROTEINS	RGPD4 RANBP2 RGPD3	4.47e-04	47	45	3	MM14939
Pathway	REACTOME_MITOTIC_SPINDLE_CHECKPOINT	RGPD4 RANBP2 RGPD3 SGO2	5.16e-04	117	45	4	MM15387
Pathway	REACTOME_TRANSPORT_OF_MATURE_MRNAS_DERIVED_FROM_INTRONLESS_TRANSCRIPTS	RGPD4 RANBP2 RGPD3	5.36e-04	50	45	3	MM14610
Pathway	REACTOME_DISEASES_OF_DNA_REPAIR	BRCA2 ATM RPA1	5.69e-04	51	45	3	M29854
Pathway	REACTOME_SUMOYLATION_OF_DNA_REPLICATION_PROTEINS	RGPD4 RANBP2 RGPD3	5.69e-04	51	45	3	MM15151
Pathway	REACTOME_NUCLEAR_ENVELOPE_BREAKDOWN	RGPD4 RANBP2 RGPD3	7.10e-04	55	45	3	MM14917
Pathway	KEGG_TIGHT_JUNCTION	MYH1 MYH4 MYH11 CLDN10	8.13e-04	132	45	4	M11355
Pathway	REACTOME_SUMOYLATION_OF_RNA_BINDING_PROTEINS	RGPD4 RANBP2 RGPD3	8.30e-04	58	45	3	MM15149
Pathway	REACTOME_SNRNP_ASSEMBLY	RGPD4 RANBP2 RGPD3	8.30e-04	58	45	3	MM14736
Pathway	REACTOME_MITOTIC_METAPHASE_AND_ANAPHASE	RGPD4 PDS5B RANBP2 RGPD3 SGO2	8.59e-04	234	45	5	MM14898
Pathway	REACTOME_HDR_THROUGH_HOMOLOGOUS_RECOMBINATION_HRR	BRCA2 ATM RPA1	8.72e-04	59	45	3	MM15283
Pathway	REACTOME_RHO_GTPASES_ACTIVATE_FORMINS	RGPD4 RANBP2 RGPD3 SGO2	1.04e-03	141	45	4	MM15266
Pathway	REACTOME_SUMOYLATION_OF_CHROMATIN_ORGANIZATION_PROTEINS	RGPD4 RANBP2 RGPD3	1.16e-03	65	45	3	MM15147
Pathway	KEGG_MEDICUS_REFERENCE_HOMOLOGOUS_RECOMBINATION_IN_ICLR	BRCA2 RPA1	1.16e-03	16	45	2	M47855
Pathway	REACTOME_RHO_GTPASE_EFFECTORS	RGPD4 RANBP2 MYH11 RGPD3 SGO2	1.30e-03	257	45	5	MM14755
Pathway	REACTOME_HDR_THROUGH_HOMOLOGOUS_RECOMBINATION_HRR	BRCA2 ATM RPA1	1.43e-03	70	45	3	M27570
Pathway	KEGG_VIRAL_MYOCARDITIS	MYH1 MYH4 MYH11	1.43e-03	70	45	3	M12294
Pathway	BIOCARTA_P53HYPOXIA_PATHWAY	ATM RPA1	2.01e-03	21	45	2	M5202
Pathway	REACTOME_SUMOYLATION	RGPD4 RANBP2 RGPD3 RPA1	2.03e-03	169	45	4	MM14919
Pathway	WP_DNA_IRDAMAGE_AND_CELLULAR_RESPONSE_VIA_ATR	BRCA2 ATM RPA1	2.18e-03	81	45	3	M39490
Pathway	BIOCARTA_ATRBRCA_PATHWAY	BRCA2 ATM	2.21e-03	22	45	2	M9703
Pathway	REACTOME_GLUCOSE_METABOLISM	RGPD4 RANBP2 RGPD3	2.26e-03	82	45	3	MM15394
Pathway	REACTOME_REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE	RANBP2 ATM RPA1	2.26e-03	82	45	3	M27250
Pathway	REACTOME_TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM	RGPD4 RANBP2 RGPD3	2.59e-03	86	45	3	MM15413
Pathway	REACTOME_MEIOTIC_RECOMBINATION	BRCA2 ATM RPA1	2.76e-03	88	45	3	M1011
Pathway	REACTOME_CELL_CYCLE	RGPD4 PDS5B RANBP2 RGPD3 SGO2 ATM RPA1	2.79e-03	603	45	7	MM14635
Pubmed	Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.	PDS5B UBE4A RANBP2 RPRD1A GTF3C1 AP1G1 NT5DC2 SGO2 HEATR1 ATM TDRD6 RPA1 AKR1B1 FTSJ3	1.04e-07	1425	60	14	30948266
Pubmed	Interconversion of red opsin isoforms by the cyclophilin-related chaperone protein Ran-binding protein 2.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	9037092
Pubmed	Genomic organization, expression, and localization of murine Ran-binding protein 2 (RanBP2) gene.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	11353387
Pubmed	Microglial activation in an amyotrophic lateral sclerosis-like model caused by Ranbp2 loss and nucleocytoplasmic transport impairment in retinal ganglion neurons.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	30944974
Pubmed	Nucleoporin Nup358 drives the differentiation of myeloid-biased multipotent progenitors by modulating HDAC3 nuclear translocation.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	38838144
Pubmed	Retina-specifically expressed novel subtypes of bovine cyclophilin.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	7559465
Pubmed	Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	17372272
Pubmed	Proteostatic Remodeling of Small Heat Shock Chaperones─Crystallins by Ran-Binding Protein 2─and the Peptidyl-Prolyl cis-trans Isomerase and Chaperone Activities of Its Cyclophilin Domain.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	38657106
Pubmed	Nup358, a nucleoporin, functions as a key determinant of the nuclear pore complex structure remodeling during skeletal myogenesis.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	21205196
Pubmed	Haploinsufficiency of RanBP2 is neuroprotective against light-elicited and age-dependent degeneration of photoreceptor neurons.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	18949001
Pubmed	Selective impairment of a subset of Ran-GTP-binding domains of ran-binding protein 2 (Ranbp2) suffices to recapitulate the degeneration of the retinal pigment epithelium (RPE) triggered by Ranbp2 ablation.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	25187515
Pubmed	Localization of the Ran-GTP binding protein RanBP2 at the cytoplasmic side of the nuclear pore complex.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	8603673
Pubmed	Uncoupling phototoxicity-elicited neural dysmorphology and death by insidious function and selective impairment of Ran-binding protein 2 (Ranbp2).	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	26632511
Pubmed	Differential loss of prolyl isomerase or chaperone activity of Ran-binding protein 2 (Ranbp2) unveils distinct physiological roles of its cyclophilin domain in proteostasis.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	24403063
Pubmed	Distinct and atypical intrinsic and extrinsic cell death pathways between photoreceptor cell types upon specific ablation of Ranbp2 in cone photoreceptors.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	23818861
Pubmed	Kinesin-1 and mitochondrial motility control by discrimination of structurally equivalent but distinct subdomains in Ran-GTP-binding domains of Ran-binding protein 2.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	23536549
Pubmed	Identification of RanBP2- and kinesin-mediated transport pathways with restricted neuronal and subcellular localization.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	12191015
Pubmed	Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	22821000
Pubmed	Neuroprotection resulting from insufficiency of RANBP2 is associated with the modulation of protein and lipid homeostasis of functionally diverse but linked pathways in response to oxidative stress.	RGPD4 RANBP2 RGPD3	1.70e-07	7	60	3	20682751
Pubmed	Transcription factor Foxp3 and its protein partners form a complex regulatory network.	RGPD4 RANBP2 GTF3C1 RGPD3 HEATR1 ATM RPA1 FTSJ3	2.40e-07	370	60	8	22922362
Pubmed	The nucleoporin RanBP2 tethers the cAMP effector Epac1 and inhibits its catalytic activity.	RGPD4 RANBP2 RGPD3	2.72e-07	8	60	3	21670213
Pubmed	Critical role of RanBP2-mediated SUMOylation of Small Heterodimer Partner in maintaining bile acid homeostasis.	RGPD4 RANBP2 RGPD3	2.72e-07	8	60	3	27412403
Pubmed	Mice lacking Ran binding protein 1 are viable and show male infertility.	RGPD4 RANBP2 RGPD3	2.72e-07	8	60	3	21310149
Pubmed	The distribution of phosphorylated SR proteins and alternative splicing are regulated by RANBP2.	RGPD4 RANBP2 RGPD3	2.72e-07	8	60	3	22262462
Pubmed	Zap70 and downstream RanBP2 are required for the exact timing of the meiotic cell cycle in oocytes.	RGPD4 RANBP2 RGPD3	2.72e-07	8	60	3	28745977
Pubmed	Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha.	RGPD4 RANBP2 RGPD3	4.07e-07	9	60	3	18394993
Pubmed	Loss of Ranbp2 in motoneurons causes disruption of nucleocytoplasmic and chemokine signaling, proteostasis of hnRNPH3 and Mmp28, and development of amyotrophic lateral sclerosis-like syndromes.	RGPD4 RANBP2 RGPD3	4.07e-07	9	60	3	28100513
Pubmed	Association of the kinesin-binding domain of RanBP2 to KIF5B and KIF5C determines mitochondria localization and function.	RGPD4 RANBP2 RGPD3	4.07e-07	9	60	3	17887960
Pubmed	The docking of kinesins, KIF5B and KIF5C, to Ran-binding protein 2 (RanBP2) is mediated via a novel RanBP2 domain.	RGPD4 RANBP2 RGPD3	4.07e-07	9	60	3	11553612
Pubmed	The zinc finger cluster domain of RanBP2 is a specific docking site for the nuclear export factor, exportin-1.	RGPD4 RANBP2 RGPD3	4.07e-07	9	60	3	10601307
Pubmed	The cyclophilin-like domain mediates the association of Ran-binding protein 2 with subunits of the 19 S regulatory complex of the proteasome.	RGPD4 RANBP2 RGPD3	4.07e-07	9	60	3	9733766
Pubmed	Impairments in age-dependent ubiquitin proteostasis and structural integrity of selective neurons by uncoupling Ran GTPase from the Ran-binding domain 3 of Ranbp2 and identification of novel mitochondrial isoforms of ubiquitin-conjugating enzyme E2I (ubc9) and Ranbp2.	RGPD4 RANBP2 RGPD3	4.07e-07	9	60	3	28877029
Pubmed	The RanBP2/RanGAP1*SUMO1/Ubc9 SUMO E3 ligase is a disassembly machine for Crm1-dependent nuclear export complexes.	RGPD4 RANBP2 RGPD3	5.81e-07	10	60	3	27160050
Pubmed	Parkin ubiquitinates and promotes the degradation of RanBP2.	RGPD4 RANBP2 RGPD3	5.81e-07	10	60	3	16332688
Pubmed	Cyclophilin-related protein RanBP2 acts as chaperone for red/green opsin.	RGPD4 RANBP2 RGPD3	5.81e-07	10	60	3	8857542
Pubmed	Ran-dependent docking of importin-beta to RanBP2/Nup358 filaments is essential for protein import and cell viability.	RGPD4 RANBP2 RGPD3	5.81e-07	10	60	3	21859863
Pubmed	RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism.	RGPD4 RANBP2 RGPD3	7.97e-07	11	60	3	17069463
Pubmed	An Rtn4/Nogo-A-interacting micropeptide modulates synaptic plasticity with age.	RGPD4 RANBP2 RGPD3	7.97e-07	11	60	3	35771867
Pubmed	T-cell receptor (TCR) signaling promotes the assembly of RanBP2/RanGAP1-SUMO1/Ubc9 nuclear pore subcomplex via PKC-θ-mediated phosphorylation of RanGAP1.	RGPD4 RANBP2 RGPD3	7.97e-07	11	60	3	34110283
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	RGPD4 PDS5B MYH1 MYH4 RANBP2 MYH11 GTF3C1 MYO5A RGPD3 HEATR1 ATM ZFC3H1 LYST	8.50e-07	1442	60	13	35575683
Pubmed	RSPO-LGR4 functions via IQGAP1 to potentiate Wnt signaling.	RGPD4 RANBP2 MYH11 HEATR1 ZFC3H1 FTSJ3	1.37e-06	202	60	6	24639526
Pubmed	Ankyrin-G induces nucleoporin Nup358 to associate with the axon initial segment of neurons.	RGPD4 RANBP2 RGPD3	1.38e-06	13	60	3	31427429
Pubmed	Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of SARS-CoV-2.	ACE2 F8 TG	2.19e-06	15	60	3	36305765
Pubmed	Limited expression of nuclear pore membrane glycoprotein 210 in cell lines and tissues suggests cell-type specific nuclear pores in metazoans.	RGPD4 RANBP2 RGPD3	2.19e-06	15	60	3	14697343
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	PDS5B ACTR1B RANBP2 GTF3C1 MYO5A AP1G1 UBE4B HEATR1 OCRL NDUFA9 RPA1 FTSJ3	2.84e-06	1353	60	12	29467282
Pubmed	The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases.	AKR1A1 AKR1B1	2.93e-06	2	60	2	2498333
Pubmed	Growth and muscle defects in mice lacking adult myosin heavy chain genes.	MYH1 MYH4	2.93e-06	2	60	2	9382868
Pubmed	Postnatal myosin heavy chain isoform expression in normal mice and mice null for IIb or IId myosin heavy chains.	MYH1 MYH4	2.93e-06	2	60	2	11150240
Pubmed	Evaluation of the prostaglandin F synthase activity of human and bovine aldo-keto reductases: AKR1A1s complement AKR1B1s as potent PGF synthases.	AKR1A1 AKR1B1	2.93e-06	2	60	2	23747692
Pubmed	Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.	BRCA2 ATM	2.93e-06	2	60	2	37126020
Pubmed	Aldose and aldehyde reductases from human kidney cortex and medulla.	AKR1A1 AKR1B1	2.93e-06	2	60	2	8268209
Pubmed	Molecular basis for PrimPol recruitment to replication forks by RPA.	RPA1 PRIMPOL	2.93e-06	2	60	2	28534480
Pubmed	A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly.	UBE4A UBE4B	2.93e-06	2	60	2	10089879
Pubmed	Characterization of ATM expression, localization, and associated DNA-dependent protein kinase activity.	ATM RPA1	2.93e-06	2	60	2	9725899
Pubmed	Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.	BRCA2 ATM	2.93e-06	2	60	2	27692705
Pubmed	Expression and activities of aldo-keto oxidoreductases in Alzheimer disease.	AKR1A1 AKR1B1	2.93e-06	2	60	2	11444797
Pubmed	Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features.	AKR1A1 AKR1B1	2.93e-06	2	60	2	18495158
Pubmed	Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.	BRCA2 ATM	2.93e-06	2	60	2	34533610
Pubmed	Human PrimPol activity is enhanced by RPA.	RPA1 PRIMPOL	2.93e-06	2	60	2	28396594
Pubmed	(5-Hydroxy-4-oxo-2-styryl-4H-pyridin-1-yl)-acetic Acid Derivatives as Multifunctional Aldose Reductase Inhibitors.	AKR1A1 AKR1B1	2.93e-06	2	60	2	33158254
Pubmed	Aldose reductase in human retinal pigment epithelial cells.	AKR1A1 AKR1B1	2.93e-06	2	60	2	8405190
Pubmed	Characterization and visualization of murine coagulation factor VIII-producing cells in vivo.	LYVE1 F8	2.93e-06	2	60	2	34290295
Pubmed	Skeletal muscle adaptations in response to voluntary wheel running in myosin heavy chain null mice.	MYH1 MYH4	2.93e-06	2	60	2	11744674
Pubmed	A direct physical interaction between Nanog and Sox2 regulates embryonic stem cell self-renewal.	RGPD4 RANBP2 BRCA2 RGPD3 SGO2	5.52e-06	146	60	5	23892456
Pubmed	Terminal differentiation of cortical neurons rapidly remodels RanGAP-mediated nuclear transport system.	RGPD4 RANBP2 RGPD3	7.34e-06	22	60	3	27717094
Pubmed	BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage.	BRCA2 PRIMPOL	8.77e-06	3	60	2	34645815
Pubmed	Transition of myosin heavy chain isoforms in human laryngeal abductors following denervation.	MYH1 MYH4	8.77e-06	3	60	2	26059207
Pubmed	BRCA2 is required for neurogenesis and suppression of medulloblastoma.	BRCA2 ATM	8.77e-06	3	60	2	17476307
Pubmed	Simultaneous loss of skeletal muscle myosin heavy chain IIx and IIb causes severe skeletal muscle hypoplasia in postnatal mice.	MYH1 MYH4	8.77e-06	3	60	2	36515178
Pubmed	Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study.	BRCA2 ATM	8.77e-06	3	60	2	15084244
Pubmed	Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.	BRCA2 ATM	8.77e-06	3	60	2	32875559
Pubmed	BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.	BRCA2 ATM	8.77e-06	3	60	2	33414135
Pubmed	Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.	AKR1A1 AKR1B1	8.77e-06	3	60	2	10510318
Pubmed	Screening for ATM sequence alterations in African-American women diagnosed with breast cancer.	BRCA2 ATM	8.77e-06	3	60	2	17333338
Pubmed	PRIMPOL competes with RAD51 to resolve G-quadruplex-induced replication stress via its interaction with RPA.	RPA1 PRIMPOL	8.77e-06	3	60	2	36647718
Pubmed	Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia.	BRCA2 ATM	8.77e-06	3	60	2	16574953
Pubmed	Architectural plasticity of human BRCA2-RAD51 complexes in DNA break repair.	BRCA2 RPA1	8.77e-06	3	60	2	28168276
Pubmed	Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?	BRCA2 ATM	8.77e-06	3	60	2	34517749
Pubmed	Ascorbate synthesis pathway: dual role of ascorbate in bone homeostasis.	AKR1A1 AKR1B1	8.77e-06	3	60	2	20410296
Pubmed	Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.	BRCA2 ATM	8.77e-06	3	60	2	29915322
Pubmed	DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.	BRCA2 ATM	8.77e-06	3	60	2	27317574
Pubmed	A role for human homologous recombination factors in suppressing microhomology-mediated end joining.	BRCA2 RPA1	8.77e-06	3	60	2	27131361
Pubmed	Substrate specificities and identification of putative substrates of ATM kinase family members.	BRCA2 ATM RPA1	1.09e-05	25	60	3	10608806
Pubmed	The ubiquitin ligase Uhrf2 is a master regulator of cholesterol biosynthesis and is essential for liver regeneration.	RGPD4 RANBP2 RGPD3 SGO2	1.53e-05	86	60	4	37253089
Pubmed	Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a Chinese Han population.	BRCA2 ATM	1.75e-05	4	60	2	20513533
Pubmed	Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction.	PDS5B BRCA2	1.75e-05	4	60	2	27924011
Pubmed	Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.	BRCA2 ATM	1.75e-05	4	60	2	17428320
Pubmed	A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.	BRCA2 ATM	1.75e-05	4	60	2	27941124
Pubmed	Three linked myosin heavy chain genes clustered within 370 kb of each other show independent transcriptional and post-transcriptional regulation during differentiation of a mouse muscle cell line.	MYH1 MYH4	1.75e-05	4	60	2	1985022
Pubmed	Smooth muscle myosin light chain kinase expression in cardiac and skeletal muscle.	MYH1 MYH4	1.75e-05	4	60	2	11029314
Pubmed	Elevated HMGN4 expression potentiates thyroid tumorigenesis.	BRCA2 ATM	1.75e-05	4	60	2	28186538
Pubmed	Promotion of BRCA2-Dependent Homologous Recombination by DSS1 via RPA Targeting and DNA Mimicry.	BRCA2 RPA1	1.75e-05	4	60	2	26145171
Pubmed	Modulation of skeletal muscle fiber type by mitogen-activated protein kinase signaling.	MYH1 MYH4	1.75e-05	4	60	2	18417546
Pubmed	Human MYO18B, a novel unconventional myosin heavy chain expressed in striated muscles moves into the myonuclei upon differentiation.	MYH1 MYH4	1.75e-05	4	60	2	12547197
Pubmed	Comparative sequence analysis of the complete human sarcomeric myosin heavy chain family: implications for functional diversity.	MYH1 MYH4	1.75e-05	4	60	2	10388558
Pubmed	A human YAC transgene rescues craniofacial and neural tube development in PDGFRalpha knockout mice and uncovers a role for PDGFRalpha in prenatal lung growth.	MYH1 MYH4	1.75e-05	4	60	2	11023856
Pubmed	Gene-gene interactions in breast cancer susceptibility.	BRCA2 ATM	1.75e-05	4	60	2	22072393
Pubmed	Complementary proteomics strategies capture an ataxin-1 interactome in Neuro-2a cells.	RGPD4 ACTR1B RANBP2 MYO5A RGPD3 NDUFA9 RPA1 FTSJ3	1.83e-05	665	60	8	30457570
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	UBE4A VPS13D MYH11 DNAH17 CNTNAP4 ZFC3H1 MYSM1	2.22e-05	493	60	7	15368895
Pubmed	KAP1 facilitates reinstatement of heterochromatin after DNA replication.	PDS5B RANBP2 GTF3C1 AP1G1 UBE4B RGPD3 HEATR1 RPA1	2.74e-05	704	60	8	29955894
Interaction	POLR1E interactions	RANBP2 RPRD1A GTF3C1 BRCA2 SGO2 HEATR1 ZFC3H1 RPA1 FTSJ3	7.59e-07	350	59	9	int:POLR1E
Interaction	KIF20A interactions	RGPD4 PDS5B ACE2 ACTR1B RANBP2 MYH11 AGO3 RBM12B RGPD3 CNTNAP4 HEATR1 NDUFA9 FTSJ3	8.53e-06	1052	59	13	int:KIF20A
Interaction	G3BP1 interactions	PDS5B ACE2 ACTR1B RANBP2 RPRD1A AGO3 RBM12B RGPD3 NFX1 RPA1 FTSJ3	2.62e-05	835	59	11	int:G3BP1
Interaction	RGPD4 interactions	RGPD4 RANBP2 RGPD3	3.53e-05	22	59	3	int:RGPD4
Interaction	MEMO1 interactions	ACE2 AKR1A1 AKR1B1 KYNU	3.93e-05	65	59	4	int:MEMO1
Interaction	TELO2 interactions	ACE2 ATM PPARD RPA1 CLDN10	4.69e-05	135	59	5	int:TELO2
Interaction	H2AX interactions	ACE2 UBE4A RANBP2 GTF3C1 BRCA2 CC2D1A ATM RPA1 MYSM1	5.26e-05	593	59	9	int:H2AX
Interaction	RGPD2 interactions	RGPD4 RANBP2 RGPD3	6.63e-05	27	59	3	int:RGPD2
Interaction	NUP43 interactions	PDS5B RANBP2 BRCA2 NETO1 HEATR1 AKR1A1 ZFC3H1 MYSM1 FTSJ3	7.88e-05	625	59	9	int:NUP43
Interaction	POLR1G interactions	PDS5B RPRD1A GTF3C1 SGO2 HEATR1 MPND ZFC3H1 FTSJ3	8.49e-05	489	59	8	int:POLR1G
Interaction	DNMT1 interactions	ACE2 BRCA2 ZFP57 NFX1 ATM RPA1	9.73e-05	254	59	6	int:DNMT1
Interaction	PRC1 interactions	PDS5B RANBP2 UBE4B RBM12B RGPD3 NFX1 CNTNAP4 HEATR1 NDUFA9 RPA1 FTSJ3	1.04e-04	973	59	11	int:PRC1
Interaction	LGR4 interactions	RGPD4 RANBP2 MYH11 HEATR1 ZFC3H1 FTSJ3	1.15e-04	262	59	6	int:LGR4
Interaction	ASAH2 interactions	MYH1 MYH4	1.25e-04	6	59	2	int:ASAH2
Interaction	RAB11A interactions	CDCA3 DENND5B ACE2 ACTR1B EFNB2 MYO5A CC2D1A OCRL RPA1 FTSJ3	1.34e-04	830	59	10	int:RAB11A
Interaction	ACTR1A interactions	DENND5B ACTR1B UBE4A NFX1 ZFC3H1 RPA1	1.47e-04	274	59	6	int:ACTR1A
Interaction	RAD17 interactions	BRCA2 ATM PPARD RPA1	1.53e-04	92	59	4	int:RAD17
Interaction	AAGAB interactions	AP1G1 HEATR1 RPA1	1.73e-04	37	59	3	int:AAGAB
Interaction	IER2 interactions	RANBP2 BRCA2 SGO2	1.73e-04	37	59	3	int:IER2
Interaction	SCN2B interactions	PDS5B HEATR1 ATM OCRL	1.73e-04	95	59	4	int:SCN2B
Interaction	PDS5B interactions	PDS5B BRCA2 UBE4B NT5DC2 RPA1	1.73e-04	178	59	5	int:PDS5B
Interaction	KIF23 interactions	MYH11 AGO3 MYO5A RBM12B CNTNAP4 HEATR1 ZFC3H1 NDUFA9 RPA1 TG FTSJ3	1.74e-04	1031	59	11	int:KIF23
Interaction	OVCA2 interactions	MYH11 KYNU	1.75e-04	7	59	2	int:OVCA2
Interaction	SBDS interactions	ACE2 MYH1 MYH4 UBE4B RPA1	1.87e-04	181	59	5	int:SBDS
Cytoband	13q12.3	PDS5B SLC46A3 BRCA2	3.21e-06	22	60	3	13q12.3
Cytoband	2q12.3	RGPD4 RANBP2	2.26e-04	17	60	2	2q12.3
Cytoband	3q13.2	SIDT1 CFAP44	7.62e-04	31	60	2	3q13.2
GeneFamily	Myosin heavy chains	MYH1 MYH4 MYH11	3.53e-06	15	37	3	1098
GeneFamily	U-box domain containing	UBE4A UBE4B	8.50e-05	7	37	2	365
GeneFamily	Aldo-keto reductases	AKR1A1 AKR1B1	4.21e-04	15	37	2	399
GeneFamily	Tetratricopeptide repeat domain containing\|Bardet-Biedl syndrome associated\|BBSome	RGPD4 RANBP2 RGPD3	1.66e-03	115	37	3	769
Coexpression	GSE27859_DC_VS_CD11C_INT_F480_HI_MACROPHAGE_UP	BRCA2 MYO5A HEATR1 ATM AKR1B1 FTSJ3	6.51e-06	200	60	6	M8597
Coexpression	GSE17721_CTRL_VS_GARDIQUIMOD_4H_BMDC_UP	CDCA3 MYO5A CC2D1A HEATR1 ATM CLDN10	6.51e-06	200	60	6	M3780
Coexpression	HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_UP	CDCA3 MYH11 BRCA2 NT5DC2 RPA1	2.68e-05	153	60	5	M5588
Coexpression	HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_UP	CDCA3 MYH11 BRCA2 NT5DC2 RPA1	2.85e-05	155	60	5	MM1259
Coexpression	GAUSSMANN_MLL_AF4_FUSION_TARGETS_B_UP	RGPD4 RANBP2 RGPD3	5.92e-05	33	60	3	MM477
Coexpression	GSE13547_CTRL_VS_ANTI_IGM_STIM_BCELL_2H_UP	CDCA3 BRCA2 MYO5A SGO2 RPA1	6.28e-05	183	60	5	M2993
ToppCell	368C-Lymphocytic-ILC-ILC-2\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	PDS5B MYH11 SGO2 RPA1 PRIMPOL	4.43e-06	180	60	5	eb5a57604c7f2ad256c300085dbf5069d0ae1ad0
ToppCell	368C-Lymphocytic-ILC\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	PDS5B MYH11 SGO2 RPA1 PRIMPOL	4.43e-06	180	60	5	ddba4dc3bbcfe4e4a22400be73bbc62d3ff27d3c
ToppCell	3'_v3-bone_marrow-Hematopoietic_progenitors-Progenitor_Myeloid\|bone_marrow / Manually curated celltypes from each tissue	CDCA3 BRCA2 NT5DC2 SGO2 CLDN10	4.68e-06	182	60	5	6745d464c3ff289726aa8164e9a43f407f8e4380
ToppCell	RA-08._Macrophage\|World / Chamber and Cluster_Paper	LYVE1 MYO5A PPARD KYNU TG	6.22e-06	193	60	5	5fd22db1825d105709fcc0aa4955c99a117e3c82
ToppCell	10x_3'_v2v3-Neoplastic-Differentiated-like-AC-like-AC-like_Prolif-E\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CDCA3 BRCA2 NT5DC2 SGO2 CLDN10	7.04e-06	198	60	5	7225a6194c52b01c581e58d3cda107c4af96dc4f
ToppCell	facs-Lung-3m-Endothelial-capillary_endothelial-capillary_endothelial_cell-capillary_type_1_endothelial_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CDCA3 MYH1 BRCA2 SGO2	4.75e-05	148	60	4	5983c4546f527a0b599cfcbd8a6cb937a1d6f895
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Myh8_Fibin\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 NT5DC2 CNTNAP4	5.98e-05	157	60	4	741d79c10cb87fa7f14080c6fccb1553c3a20bad
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Chrna2_Glra3\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 NT5DC2 CNTNAP4	6.43e-05	160	60	4	0bfdaf979e6f128cba2928ce16bca4d3deff8ac9
ToppCell	390C-Endothelial_cells-Endothelial-E\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	UBE4B SIDT1 CC2D1A CFAP44	6.75e-05	162	60	4	45be019b50e3727fc9d3fad2ff78e74e4f2d746b
ToppCell	390C-Endothelial_cells-Endothelial-E-\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	UBE4B SIDT1 CC2D1A CFAP44	6.75e-05	162	60	4	fbb0cc2b1434a340dc35058b77c73ea61004c252
ToppCell	Club-club-13\|World / Class top	ACE2 SIDT1 AKR1A1 CLDN10	6.75e-05	162	60	4	7d18f05a65ac715e62d610df9cc4a26539340dee
ToppCell	PND10-Epithelial-Epithelial_Airway-Neurosecretory-Secretory-Secretory_G2M\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CDCA3 SGO2 CLDN10 TG	7.59e-05	167	60	4	a90f905ef38437752e2b0b71bd0322a184de1861
ToppCell	facs-Lung-Endomucin-3m-Mesenchymal-pericyte_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYH11 AGO3 NT5DC2 OCRL	7.95e-05	169	60	4	2d23b4cee060f8adddc430c1c10d4e25205b4af6
ToppCell	facs-Lung-Endomucin-3m-Mesenchymal-Pericyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYH11 AGO3 NT5DC2 OCRL	7.95e-05	169	60	4	ecaf08e8e0b54d1c97a02bc1f65409fd43d68227
ToppCell	facs-Lung-Endomucin-3m-Mesenchymal\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYH11 AGO3 NT5DC2 OCRL	7.95e-05	169	60	4	ad6af6609acf158cb79e45ee7ca9af332be3c40c
ToppCell	368C-Lymphocytic-ILC\|368C / Donor, Lineage, Cell class and subclass (all cells)	PDS5B MYH11 SGO2 RPA1	8.32e-05	171	60	4	3b3143e4aa6520ee9c6b6f2482206ad3d8205d14
ToppCell	368C-Lymphocytic-ILC-ILC-2\|368C / Donor, Lineage, Cell class and subclass (all cells)	PDS5B MYH11 SGO2 RPA1	8.32e-05	171	60	4	fd01076574dcc82bfd4a1538812500543b16794f
ToppCell	facs-Thymus-Flowthrough-3m-Myeloid\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DENND5B MYO5A ZFP57 KYNU	8.51e-05	172	60	4	356a66cd9303470e427005cc67fdd22a2c4bf971
ToppCell	facs-Thymus-Flowthrough-3m-Myeloid-macrophage\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DENND5B MYO5A ZFP57 KYNU	8.51e-05	172	60	4	46fadeee483fdf8402df92ec98575a09c6c15b16
ToppCell	facs-Thymus-Flowthrough-3m-Myeloid-macrophage\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DENND5B MYO5A ZFP57 KYNU	8.51e-05	172	60	4	438d2e7f1897668a14d85ca70722e5d0102606dc
ToppCell	PND10-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC-EPC_prolif\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CDCA3 LYVE1 SGO2 RPA1	8.90e-05	174	60	4	c988471207ba06195bc3e41056435e8c31c20bbe
ToppCell	Healthy/Control-Plasmablast\|Healthy/Control / Disease group and Cell class	DENND5B NT5DC2 GRIK4 TG	8.90e-05	174	60	4	97d19ef3240a1f648c6befaabb9ce45ad469cbce
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_ascending_limb_epithelial_cell-Degenerative_Ascending_Thin_Limb_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DNAH17 GRIK4 AKR1B1 CLDN10	8.90e-05	174	60	4	46bd0ef7d0541386de7a901d85d53d0176dc92bf
ToppCell	PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_G2M\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CDCA3 MYH1 MYH11 SGO2	9.30e-05	176	60	4	45c6983ab671b0f306e7390320bd84f848e474cc
ToppCell	356C-Myeloid-Dendritic-cDC_proliferating_2\|356C / Donor, Lineage, Cell class and subclass (all cells)	CDCA3 LYVE1 BRCA2 SGO2	9.30e-05	176	60	4	4bba41ebf9dd187c8705a6997ed039878de62b4e
ToppCell	facs-Lung-24m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l25\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	LYVE1 EFNB2 MTERF2 ZFP57	1.01e-04	180	60	4	baa5825e6ce23a98d9c21d024a4b0ab8ba353d0c
ToppCell	facs-Lung-24m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	LYVE1 EFNB2 MTERF2 ZFP57	1.01e-04	180	60	4	2d608b9394d28d19cfc85c6ac94003d5177c8a92
ToppCell	facs-Lung-24m-Endothelial-arterial_endothelial\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	LYVE1 EFNB2 MTERF2 ZFP57	1.01e-04	180	60	4	0f9b27054358c4737eed06c8ea01987cccc3cb55
ToppCell	5'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_proliferating-Alveolar_macrophage_proliferating_L.1.0.7.2\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CDCA3 BRCA2 RGPD3 SGO2	1.04e-04	181	60	4	73b1b59810f60e3e39ca1d5073a5a0d4f5377e6e
ToppCell	nucseq-Immune-Lymphocytic_B-Lymphocytic_B-B\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	DENND5B NETO1 SIDT1 ATM	1.04e-04	181	60	4	8d8cc4dae2c8bd5f4b1c159f2a52edc4c9449c86
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_ascending_limb_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	DNAH17 GRIK4 AKR1B1 CLDN10	1.08e-04	183	60	4	83592c332b1e82673f993d37c7f480befdc3dcda
ToppCell	facs-Diaphragm-Limb_Muscle-18m-Lymphocytic-T_cell\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CDCA3 BRCA2 NT5DC2 SGO2	1.10e-04	184	60	4	185b49630da61cbf45c0926d1b992943296d2a54
ToppCell	saliva-Severe-critical_progression_d12-22_no-steroids-Myeloid-Macrophage-macrophage,_alveolar-Macro_c1-C1QC\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	SLC46A3 ZFP57 AKR1A1 TDRD6	1.13e-04	185	60	4	0e8064bb317f26959d3c59b4f73d0c455161ccd7
ToppCell	COVID-19-lung-B_cells\|COVID-19 / Disease (COVID-19 only), tissue and cell type	DENND5B NETO1 SIDT1 ATM	1.13e-04	185	60	4	e8f1ad580f19705b5ca1d7d8867b2125f4891684
ToppCell	Control-Endothelial-Endothelial-Artery\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	EFNB2 CNTNAP4 AKR1B1 CLDN10	1.15e-04	186	60	4	2d3a975d2bf92e18e3410dd413fc9f84831d82de
ToppCell	facs-Diaphragm-Limb_Muscle-18m-Lymphocytic\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CDCA3 BRCA2 NT5DC2 SGO2	1.17e-04	187	60	4	e53471c3e146a6f54788d81ecc469aba55b051bb
ToppCell	facs-Diaphragm-Limb_Muscle-18m-Lymphocytic-nan\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CDCA3 BRCA2 NT5DC2 SGO2	1.17e-04	187	60	4	3d7d51fbadb20dc884d0b3c0d61b80f022b19d09
ToppCell	3'-Broncho-tracheal-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYO5A ZFP57 AKR1B1 KYNU	1.22e-04	189	60	4	1f4fe19e500bfedd48b1f34827a44e796f6db3e1
ToppCell	LPS-IL1RA+antiTNF-Endothelial-Endothelial-Artery\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	EFNB2 CNTNAP4 AKR1B1 CLDN10	1.22e-04	189	60	4	c45734970036e6d28d5e3fe7c9458fae38a3f624
ToppCell	3'-Broncho-tracheal-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+-Alveolar_macrophage_CCL3+_L.1.0.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYO5A ZFP57 AKR1B1 KYNU	1.22e-04	189	60	4	bfa1dfc93ad33a9dbef316c0591b950d062b35eb
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Artery\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	EFNB2 CNTNAP4 AKR1B1 CLDN10	1.25e-04	190	60	4	aed65d584ca0c25f6a8313c66b421a6618af82ea
ToppCell	3'_v3-GI_small-bowel-Lymphocytic_T_CD4/8-lo-Cycling_T\|GI_small-bowel / Manually curated celltypes from each tissue	CDCA3 BRCA2 SGO2 CLDN10	1.27e-04	191	60	4	e642fa7395c05fb53324c9d46bbc52f89fc9673f
ToppCell	wk_15-18-Endothelial-Lymph_endothelial-Intermediate_lymphatic_endo\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	LYVE1 EFNB2 TNXB F8	1.27e-04	191	60	4	d25ac3206fe205a100cfee26431ff32c14c1938f
ToppCell	COPD-Endothelial-VE_Arterial\|Endothelial / Disease state, Lineage and Cell class	EFNB2 SIDT1 LYST CLDN10	1.27e-04	191	60	4	ef16ad1c1cd2c0c0377957398c98775b62a81754
ToppCell	droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal-unknown\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ACE2 MYH1 MYH4 MYH11	1.27e-04	191	60	4	f932980baa032748857cb367a55c37dd975c693e
ToppCell	RV-08._Macrophage\|World / Chamber and Cluster_Paper	LYVE1 BRCA2 MYO5A KYNU	1.30e-04	192	60	4	a1b5dc5beb97a23729b97b54fb4574d10d8fbfb3
ToppCell	RV-08._Macrophage\|RV / Chamber and Cluster_Paper	LYVE1 BRCA2 MYO5A KYNU	1.33e-04	193	60	4	12bf98a280f87e4d8f0c6887dfc855da72e47ac1
ToppCell	343B-Endothelial_cells-Endothelial-B_(Artery)\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	EFNB2 AKR1B1 F8 CLDN10	1.35e-04	194	60	4	582db7f7fa9aa08027ae18ed607945b5d1dc908a
ToppCell	LA-08._Macrophage\|World / Chamber and Cluster_Paper	LYVE1 BRCA2 MYO5A KYNU	1.35e-04	194	60	4	c1805572bcc11b1cd29083329d7b5911489fb758
ToppCell	RA-08._Macrophage\|RA / Chamber and Cluster_Paper	LYVE1 MYO5A KYNU TG	1.35e-04	194	60	4	ac26e5c71d5069622de72fa25a9c920887ac2c19
ToppCell	343B-Endothelial_cells-Endothelial-B_(Artery)-\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	EFNB2 AKR1B1 F8 CLDN10	1.35e-04	194	60	4	bda89111386398a072b70e8153b2a762298a047a
ToppCell	LA-08._Macrophage\|LA / Chamber and Cluster_Paper	LYVE1 BRCA2 MYO5A KYNU	1.38e-04	195	60	4	5e1d5bdb8874091f5a2b1d0a8cc9008165718a97
ToppCell	3'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_proliferating-Alveolar_macrophage_proliferating_L.1.0.7.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CDCA3 BRCA2 SGO2 KYNU	1.41e-04	196	60	4	35cc0986dc3fc4b89e960a565b8f9810b1688e09
ToppCell	Transplant_Alveoli_and_parenchyma-Endothelial\|Transplant_Alveoli_and_parenchyma / Tissue, Lineage and Cell class of Lung Cells from 10X	LYVE1 EFNB2 F8 CLDN10	1.46e-04	198	60	4	56b746e5791b47fe33a7872f0942ae0747b13d4a
ToppCell	Sigmoid-T_cell-Tcm\|T_cell / Region, Cell class and subclass	RGPD3 OCRL MPND PPARD	1.49e-04	199	60	4	acdf95f4d58df47690f4ae254245bc618f9ac07e
ToppCell	Parenchymal-10x5prime-Endothelial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	LYVE1 EFNB2 TNXB F8	1.52e-04	200	60	4	0e648e9eb96c83a94505d07323785a7a40997eb0
ToppCell	Lung_Parenchyma-Control-Myeloid-Macrophage-Macrophages-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	LYVE1 EFNB2 F8 CLDN10	1.52e-04	200	60	4	98f6a86fbbe5305c71dae91e7278de9813827935
ToppCell	10x_3'_v2v3-Neoplastic-Differentiated-like-AC-like-AC-like_Prolif\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CDCA3 NT5DC2 SGO2 CLDN10	1.52e-04	200	60	4	0de9e7412a1725a8acd51820aa3135a112ced36c
ToppCell	Parenchyma_Control_(B.)-Endothelial-TX-Macrophages\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	LYVE1 EFNB2 F8 CLDN10	1.52e-04	200	60	4	d7b89a721988660d8010c804916f5d0ef2520ee2
ToppCell	Lung_Parenchyma-Control-Myeloid-Macrophage-Macrophages\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	LYVE1 EFNB2 F8 CLDN10	1.52e-04	200	60	4	1ed1c673184f0c6aae04f90edbb1383b1c1f64d9
ToppCell	Lung_Parenchyma-Control-Myeloid-Macrophage\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	LYVE1 EFNB2 F8 CLDN10	1.52e-04	200	60	4	2a1ba87ca4adf351ef8fa2b3154b86a5407b8f2f
ToppCell	Biopsy_IPF-Endothelial\|Biopsy_IPF / Sample group, Lineage and Cell type	LYVE1 EFNB2 TNXB F8	1.52e-04	200	60	4	7ccd3b617838b39da814278dc0e12384013401ce
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Artery\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	EFNB2 CNTNAP4 AKR1B1 CLDN10	1.52e-04	200	60	4	b1ff8d61b567f85006d6d20093f9c803b6d34674
ToppCell	Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Rgs5Acta2.Ccnd1_(Mural.Rgs5Acta2.Ccnd1)\|Striatum / BrainAtlas - Mouse McCarroll V32	ACE2 MYH1 MYH11	2.95e-04	96	60	3	d98df92856840602a82d3f050bf0a1543445cac0
ToppCell	Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Rgs5Acta2.Ccnd1_(Mural.Rgs5Acta2.Ccnd1)-\|Striatum / BrainAtlas - Mouse McCarroll V32	ACE2 MYH1 MYH11	2.95e-04	96	60	3	bf62c29da66aa3eefdc59337dfb3cd0467f04f10
ToppCell	Frontal_cortex-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Rgs5Acta2.Abcc9_(Mural.Rgs5Acta2.Abcc9)-\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	ACE2 TNXB KYNU	3.52e-04	102	60	3	8c4d9483ff983538593f4e17f4a74a93cdda59c4
ToppCell	Frontal_cortex-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Rgs5Acta2.Abcc9_(Mural.Rgs5Acta2.Abcc9)\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	ACE2 TNXB KYNU	3.52e-04	102	60	3	72ce247dad7404e6b9c971b5c29d3c6846da5efc
ToppCell	Frontal_cortex-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	ACE2 TNXB KYNU	3.52e-04	102	60	3	5feedce6d26a578c4aaba4e4824b3d0c3f3806bc
ToppCell	facs-Lung-Endomucin-24m-Endothelial-Artery_endothelial_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LYVE1 EFNB2 MTERF2	5.53e-04	119	60	3	c3f1223356e7f245a460ea5568a223e34e458dc1
ToppCell	Posterior_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_1\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	RANBP3L TNXB KYNU	6.09e-04	123	60	3	28be15b759c152662b29c323b1cc3f02f7830dbe
ToppCell	TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Undifferentiated_Pleomorphic_Sarcoma-7\|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9	RGPD4 NETO1 NT5DC2	6.68e-04	127	60	3	c4809d8502f460370f824719d69b13b400a2b202
ToppCell	droplet-Heart-HEART-1m-Hematologic-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	VPS13D AGO3 HEATR1	6.68e-04	127	60	3	983489a69d3b1f1fe21110a862ac1dba53e9d31c
ToppCell	LPS-IL1RA+antiTNF-Unknown-Endothelial\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYH11 RANBP3L CLDN10	7.48e-04	132	60	3	46c80eab16a70da9f363a9fbdf50bccab0b287d7
ToppCell	LPS-IL1RA+antiTNF-Unknown\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYH11 RANBP3L CLDN10	7.48e-04	132	60	3	a022c3c41654166cb106f27dc54fa88e8c40f898
ToppCell	Cerebellum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3\|Cerebellum / BrainAtlas - Mouse McCarroll V32	ACE2 MYH11 TNXB	7.81e-04	134	60	3	8a3acf32cabc37b49d6488d43cdaae7cec79d119
ToppCell	Cerebellum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Acta2Rgs5.Rgs5_(Mural.Acta2Rgs5.Rgs5)\|Cerebellum / BrainAtlas - Mouse McCarroll V32	ACE2 MYH11 TNXB	7.81e-04	134	60	3	1fa13185a4dfb4563473184c0c4f449011d88631
ToppCell	Cerebellum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Acta2Rgs5.Rgs5_(Mural.Acta2Rgs5.Rgs5)-\|Cerebellum / BrainAtlas - Mouse McCarroll V32	ACE2 MYH11 TNXB	7.81e-04	134	60	3	1ab99a22d0d7657f62f8ea7d96bb24e88de54fd4
ToppCell	TCGA-Peripheral_Nervous_System-Primary_Tumor-Paraganglioma-Paraganglioma-3\|TCGA-Peripheral_Nervous_System / Sample_Type by Project: Shred V9	AP1G1 RBM12B ATM	7.98e-04	135	60	3	ac20133d4a36f48338b45bffb13e842cb66f83ad
ToppCell	PND01-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_G2M\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CDCA3 MYO5A SGO2	9.23e-04	142	60	3	be63c48794a227ea55978524c0f5935342fc455e
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Myh8_Etv1_\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MYH1 MYH4 CNTNAP4	1.04e-03	148	60	3	4d43efee96a6493abd78e9ca41aab73db0c80626
ToppCell	droplet-Liver-LIVER_HEPATOCYTES-30m-Myeloid-macrophage/monocyte\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYO5A LYST MYSM1	1.06e-03	149	60	3	48fca6ae33d7722c024b43ce04f4dbce7b6b424b
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Fibroblasts-Monocytes-Macrophages\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	LYVE1 CNTNAP4 F8	1.10e-03	151	60	3	f13a117ae26ae525da4f3e837d8f204d00dc6ee3
ToppCell	PBMC-Severe-cDC_3\|Severe / Compartment, Disease Groups and Clusters	CDCA3 DENND5B ZFP57	1.12e-03	152	60	3	1a3f8ed476aa9a39742b4684be2c704669e4a3d0
ToppCell	Globus_pallidus-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cyth3_(Cyth3)-\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	RPRD1A AP1G1 MYSM1	1.14e-03	153	60	3	553dff9688a1996d8f4ba16e60c683593d781389
ToppCell	Severe-B_naive-5\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	EFNB2 RGPD3 LYST	1.14e-03	153	60	3	44572f87d403e314050ab935d2cd676c33d9c287
ToppCell	Globus_pallidus-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cyth3_(Cyth3)\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	RPRD1A AP1G1 MYSM1	1.14e-03	153	60	3	88ca2d2c2ab19fbee13e18951b993ee05dd30f67
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Mesenchymal-immature_mesenchymal_cell-Mesoderm_1_(HAND1+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	AP1G1 F8 CLDN10	1.14e-03	153	60	3	991782d111d66e25b40319d4e6dea40f2c2c0805
ToppCell	LPS-IL1RA+antiTNF-Unknown-Endothelial-Myofibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYH11 CC2D1A CLDN10	1.17e-03	154	60	3	16fdafb5c64d2db321554f87129a962d113f1668
ToppCell	PND07-28-samps-Lymphocyte-T_cells\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	CDCA3 SIDT1 RPA1	1.23e-03	157	60	3	f3b4cde52423246ae6fc4924cd1ee502cf6c009c
ToppCell	Severe-B_naive-5\|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)	EFNB2 RGPD3 LYST	1.23e-03	157	60	3	a57ee4a6febdff3ee3d1645836695e6e7c055cf8
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Fibroblasts-Pericyte_2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CFAP44 F8 CLDN10	1.26e-03	158	60	3	7f5426585d0d299d2b48e5fcb349950feffdef33
ToppCell	PND14-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-CD8_T-CD8_T_prolif\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	BRCA2 SIDT1 RPA1	1.28e-03	159	60	3	e9c51e611ebd427bbe51e3e036c14122c36ea372
ToppCell	356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	OCRL TNXB F8	1.28e-03	159	60	3	1472536eea61d4f13033efe42f128bae1614fa74
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYH11 CNTNAP4 TDRD6	1.30e-03	160	60	3	c381ec6be8cf887861cc18f831a20db42f953fe1
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYH11 CNTNAP4 TDRD6	1.30e-03	160	60	3	25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_C_(NP)-Glut_NP_L5/6_FEZF2-Exc_L5-6_FEZF2_CABP7\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MYH1 MYH4 IFNA8	1.33e-03	161	60	3	a232401010fe2f100dce585899b66f767c208d9d
ToppCell	droplet-Lung-3m-Hematologic-lymphocytic-Zbtb32+_B_cell-Zbtb32+_B_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	AKR1B1 KYNU TG	1.33e-03	161	60	3	7af3b0d4fc7967f6b3e2d255d23fd8b1fd01a7af
ToppCell	droplet-Lung-3m-Hematologic-lymphocytic-Zbtb32+_B_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	AKR1B1 KYNU TG	1.33e-03	161	60	3	98be0cf8228496b31f7f3e0efd8787e95eb626d1
ToppCell	PND10-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC-EPC_mature\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	LYVE1 SGO2 F8	1.37e-03	163	60	3	3efbbdc9cb2613bb76d8c2f07cd4ec1a2c51a622
ToppCell	LPS-antiTNF-Endothelial-Endothelial-FOXM1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CDCA3 BRCA2 SGO2	1.37e-03	163	60	3	5285318c52aa31c9b22dc2ffff078e32e408604d
Drug	blebbistatin	ACTR1B MYH1 MYH4 MYH11 EFNB2 MYO5A	5.55e-07	116	59	6	CID003476986
Drug	4-hydroxynonanoate	NETO1 AKR1A1 AKR1B1	9.17e-07	8	59	3	CID000134653
Drug	candesartan cilexetil	ACE2 ACTR1B MYH1 MYH4 MYH11 MYO5A	2.05e-06	145	59	6	CID000002540
Drug	carvedilol	ACE2 MYH1 MYH4 MYH11 MYO5A NETO1	3.76e-06	161	59	6	CID000002585
Drug	hydroxyvaline	NETO1 AKR1A1 AKR1B1 LYST	4.23e-06	42	59	4	CID000095562
Drug	myricitrin	NETO1 AKR1A1 AKR1B1 LYST	5.60e-06	45	59	4	CID005281673
Drug	6-fluorocholesterol	ATM LYST	6.60e-06	2	59	2	CID000135206
Drug	25-fluorocholesterol	ATM LYST	6.60e-06	2	59	2	CID006454807
Drug	formycin triphosphate	MYH1 MYH4 MYH11 MYO5A	9.28e-06	51	59	4	CID000122274
Drug	D-triiodothyronine	ACTR1B MYH1 MYH4 MYH11 MYO5A AKR1A1 AKR1B1 TG	1.01e-05	409	59	8	CID000000861
Drug	NS-398; Up 200; 10uM; PC3; HT_HG-U133A	UBE4B DNAH17 NFX1 PPARD LYST KYNU	1.23e-05	198	59	6	6892_UP
Drug	Trifluoperazine dihydrochloride [440-17-5]; Down 200; 8.4uM; PC3; HT_HG-U133A	VPS13D SLC46A3 GTF3C1 CC2D1A CFAP44 F8	1.23e-05	198	59	6	6341_DN
Drug	Nifenazone [2139-47-1]; Up 200; 13uM; HL60; HG-U133A	VPS13D BRCA2 UBE4B SIDT1 CC2D1A ATM	1.27e-05	199	59	6	1439_UP
Drug	B0683	ACTR1B MYH1 MYH4 MYH11 MYO5A	1.32e-05	117	59	5	CID006398969
Drug	purealin	MYH1 MYH4 MYH11 MYO5A	1.55e-05	58	59	4	CID006419303
Drug	4-hydroxynonanal	NETO1 AKR1B1	1.98e-05	3	59	2	CID014048405
Drug	3-nitrobenzaldehyde	AKR1A1 AKR1B1	1.98e-05	3	59	2	ctd:C050571
Drug	AC1L1FH8	LYVE1 AKR1A1 AKR1B1	2.46e-05	22	59	3	CID000003235
Drug	AC1NRBPQ	ACTR1B MYH1 MYH4 MYH11 MYO5A	2.83e-05	137	59	5	CID005288569
Drug	5-Isothiocyanatoalrestatin	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID000124861
Drug	5-azidoalrestatin	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID000128442
Drug	5-(3-Thienyl)tetrazol-1-yl)acetic acid	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID003035658
Drug	hepta-2,4-dienal	NETO1 AKR1B1	3.95e-05	4	59	2	CID000020307
Drug	FR-62765	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID000128354
Drug	M7HEQ	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID006452329
Drug	NAP-HEX-Q	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID005487149
Drug	WF-2421	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID000195567
Drug	danshenol B	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID003083515
Drug	iodomethanesulfonamide	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID000519939
Drug	salviaflaside	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID006438919
Drug	matteuorienate A	AKR1A1 AKR1B1	3.95e-05	4	59	2	CID000190958
Drug	Phenylglyoxal	AKR1A1 AKR1B1	3.95e-05	4	59	2	ctd:D010658
Drug	wartmannin	ACTR1B MYH1 LYVE1 MYH4 MYH11 MYO5A AP1G1 ATM RPA1 TG	4.02e-05	811	59	10	CID000005691
Drug	zopolrestat	LYVE1 AKR1A1 AKR1B1	4.63e-05	27	59	3	CID000001613
Drug	M79175	AKR1A1 AKR1B1	6.57e-05	5	59	2	CID000115090
Drug	xanthone-2	AKR1A1 AKR1B1	6.57e-05	5	59	2	CID005384285
Drug	16-ketoestrone	AKR1A1 AKR1B1	6.57e-05	5	59	2	ctd:C002591
Drug	AC1L4VGL	AKR1A1 AKR1B1	6.57e-05	5	59	2	CID000213726
Drug	4-chloro-3-nitrobenzaldehyde	AKR1A1 AKR1B1	6.57e-05	5	59	2	CID000085505
Drug	2,3-hexanedione	AKR1A1 AKR1B1	6.57e-05	5	59	2	ctd:C043231
Drug	ICI 105552	AKR1A1 AKR1B1	6.57e-05	5	59	2	CID000133677
Drug	2-(2,3,6-Trihydroxy-4-carboxyphenyl)ellagic acid	AKR1A1 AKR1B1	6.57e-05	5	59	2	CID006918808
Drug	ICI 222155	AKR1A1 AKR1B1	6.57e-05	5	59	2	CID000195716
Drug	DN-108	AKR1A1 AKR1B1	6.57e-05	5	59	2	CID000183791
Drug	AD-5467	AKR1A1 AKR1B1	6.57e-05	5	59	2	CID000197383
Drug	BAL-ARI8	AKR1A1 AKR1B1	6.57e-05	5	59	2	CID000130098
Drug	Sulindac	PPARD AKR1B1	6.57e-05	5	59	2	DB00605
Drug	SM-2	ACTR1B MYH1 MYH4 MYH11	7.71e-05	87	59	4	CID000486033
Drug	Wy-14,643	NETO1 NFX1 AKR1A1 PPARD AKR1B1 F8	9.61e-05	286	59	6	CID000005694
Drug	ICI 215918	AKR1A1 AKR1B1	9.84e-05	6	59	2	CID000129688
Drug	AC1L28UN	AKR1A1 AKR1B1	9.84e-05	6	59	2	CID000068017
Drug	M16287	AKR1A1 AKR1B1	9.84e-05	6	59	2	CID000188399
Drug	p225	AKR1A1 AKR1B1	9.84e-05	6	59	2	CID000014589
Drug	ADN-138	AKR1A1 AKR1B1	9.84e-05	6	59	2	CID000127323
Drug	BAPSG	AKR1A1 AKR1B1	9.84e-05	6	59	2	CID000130998
Drug	capillarisin	AKR1A1 AKR1B1	9.84e-05	6	59	2	CID005281342
Drug	AC1L1GXW	ACTR1B MYH1 MYO5A F8	1.04e-04	94	59	4	CID000003891
Drug	AC1N9J6O	ACE2 AP1G1 NETO1 ATM AKR1B1	1.09e-04	182	59	5	CID004411483
Drug	Minocycline hydrochloride [13614-98-7]; Up 200; 8uM; HL60; HT_HG-U133A	DNAH17 OCRL PPARD F8 KYNU	1.30e-04	189	59	5	2405_UP
Drug	S-(-)-Etomoxir	MYH1 MYH4 MYH11 MYO5A	1.32e-04	100	59	4	CID000060765
Drug	AC1L1IZ2	ACTR1B MYH1 MYH4 MYH11 GTF3C1 MYO5A	1.34e-04	304	59	6	CID000004795
Drug	4-nitrobenzaldehyde	AKR1A1 AKR1B1	1.37e-04	7	59	2	ctd:C029915
Drug	myrciacitrin I	AKR1A1 AKR1B1	1.37e-04	7	59	2	CID000183137
Drug	friedelane	AKR1A1 AKR1B1	1.37e-04	7	59	2	CID000634354
Drug	tetramethylene glutaric acid	AKR1A1 AKR1B1	1.37e-04	7	59	2	CID000085558
Drug	guaijaverin	AKR1A1 AKR1B1	1.37e-04	7	59	2	CID005317847
Drug	desmanthin-1	AKR1A1 AKR1B1	1.37e-04	7	59	2	CID005316590
Drug	NSC107658	ACTR1B MYH1 MYH4 MYH11 MYO5A TG	1.39e-04	306	59	6	CID000002919
Drug	Perphenazine [58-39-9]; Up 200; 10uM; HL60; HG-U133A	UBE4B RBM12B ATM OCRL KYNU	1.44e-04	193	59	5	2040_UP
Drug	AC1L1O7J	RANBP2 AKR1A1 AKR1B1 LYST	1.54e-04	104	59	4	CID000007189
Drug	Enalapril maleate [76095-16-4]; Down 200; 8.2uM; PC3; HT_HG-U133A	PDS5B VPS13D BRCA2 PPARD F8	1.54e-04	196	59	5	7265_DN
Drug	aspirin, USP; Down 200; 100uM; HL60; HT_HG-U133A	EFNB2 GTF3C1 UBE4B OCRL CFAP44	1.58e-04	197	59	5	1145_DN
Drug	Terbutaline hemisulfate [23031-32-5]; Down 200; 7.2uM; MCF7; HT_HG-U133A	PDS5B SLC46A3 BRCA2 UBE4B PPARD	1.58e-04	197	59	5	6240_DN
Drug	alloxan	NETO1 AKR1A1 AKR1B1 KYNU	1.60e-04	105	59	4	CID000005781
Drug	SB 203580; Up 200; 1uM; PC3; HT_HG-U133A	UBE4B DNAH17 NFX1 LYST KYNU	1.69e-04	200	59	5	6894_UP
Drug	NSC226080	ACTR1B MYH1 MYH4 MYH11 MYO5A NFX1 ATM PPARD RPA1	1.71e-04	782	59	9	CID000005040
Drug	fast white	MYH1 MYH4 MYH11	1.77e-04	42	59	3	CID000024008
Drug	Risarestat	AKR1A1 AKR1B1	1.83e-04	8	59	2	CID000133264
Drug	1,2-diaminoguanidine	AKR1A1 AKR1B1	1.83e-04	8	59	2	CID000170039
Drug	CP-166,572	AKR1A1 AKR1B1	1.83e-04	8	59	2	CID000132302
Drug	eutypine	AKR1B1 LYST	1.83e-04	8	59	2	CID000129326
Drug	SG-210	AKR1A1 AKR1B1	1.83e-04	8	59	2	CID000132542
Drug	3 Na	LYVE1 AKR1B1	1.83e-04	8	59	2	CID000157838
Drug	phthalic acid	NETO1 NFX1 PPARD F8	1.85e-04	109	59	4	CID000001017
Drug	nocodazole	ACTR1B MYH1 MYH4 RANBP2 MYH11 MYO5A TG	2.26e-04	477	59	7	CID000004122
Drug	oregon green 488 carboxylate	NFX1 AKR1A1 AKR1B1	2.32e-04	46	59	3	CID005289081
Drug	Solvent Yellow-?14	AKR1A1 AKR1B1 F8	2.32e-04	46	59	3	CID005354458
Drug	NO-1886	NETO1 PPARD AKR1B1	2.32e-04	46	59	3	CID000131601
Drug	AL3152	AKR1A1 AKR1B1	2.35e-04	9	59	2	CID000159501
Drug	DGM-2	LYST F8	2.35e-04	9	59	2	CID000016891
Drug	4-hydroxyoctenal	NETO1 AKR1B1	2.35e-04	9	59	2	CID005283334
Drug	AC1Q5HJP	AKR1A1 AKR1B1	2.35e-04	9	59	2	CID000000067
Drug	3-deoxyfructose	AKR1A1 AKR1B1	2.35e-04	9	59	2	CID003080627
Drug	potassium amyl xanthate	AKR1A1 AKR1B1	2.35e-04	9	59	2	CID000017635
Drug	v 70	BRCA2 NETO1	2.35e-04	9	59	2	CID000085867
Drug	NSC2801	RANBP2 MYH11 AKR1B1	2.47e-04	47	59	3	CID000000471
Drug	oxovanadium	MYH1 MYH4 MYH11 F8	2.67e-04	120	59	4	CID000024411
Drug	2,3-hexanedione	AKR1A1 AKR1B1	2.93e-04	10	59	2	CID000019707
Drug	methacryloyl chloride	LYST F8	2.93e-04	10	59	2	CID000013528
Drug	3-fluoro-3-deoxy-D-glucose	AKR1A1 AKR1B1	2.93e-04	10	59	2	CID000122305
Disease	infertility (implicated_via_orthology)	BRCA2 ATM	6.86e-05	7	54	2	DOID:5223 (implicated_via_orthology)
Disease	upper aerodigestive tract neoplasm	PDS5B BRCA2 ZFP57 HEATR1 TNXB	8.76e-05	246	54	5	EFO_0004284
Disease	diabetic retinopathy (is_implicated_in)	ACE2 AKR1B1 MYSM1	1.07e-04	50	54	3	DOID:8947 (is_implicated_in)
Disease	Peripheral Nervous System Diseases	MYO5A PPARD LYST	1.35e-04	54	54	3	C4721453
Disease	dilated cardiomyopathy 1S (implicated_via_orthology)	MYH1 MYH4	1.47e-04	10	54	2	DOID:0110454 (implicated_via_orthology)
Disease	autosomal dominant hyaline body myopathy (implicated_via_orthology)	MYH1 MYH4	1.47e-04	10	54	2	DOID:0111269 (implicated_via_orthology)
Disease	congenital myopathy 6 (implicated_via_orthology)	MYH1 MYH4	1.47e-04	10	54	2	DOID:0080719 (implicated_via_orthology)
Disease	distal arthrogryposis type 2B3 (implicated_via_orthology)	MYH1 MYH4	1.47e-04	10	54	2	DOID:0111602 (implicated_via_orthology)
Disease	inclusion body myositis (implicated_via_orthology)	MYH1 MYH4	1.47e-04	10	54	2	DOID:3429 (implicated_via_orthology)
Disease	distal arthrogryposis type 2A (implicated_via_orthology)	MYH1 MYH4	1.47e-04	10	54	2	DOID:0111605 (implicated_via_orthology)
Disease	familial hypertrophic cardiomyopathy (implicated_via_orthology)	MYH1 MYH4	1.47e-04	10	54	2	DOID:0080326 (implicated_via_orthology)
Disease	distal arthrogryposis type 1 (implicated_via_orthology)	MYH1 MYH4	1.47e-04	10	54	2	DOID:0111596 (implicated_via_orthology)
Disease	distal myopathy (implicated_via_orthology)	MYH1 MYH4	2.14e-04	12	54	2	DOID:11720 (implicated_via_orthology)
Disease	myotonia congenita (implicated_via_orthology)	MYH1 MYH4	2.14e-04	12	54	2	DOID:2106 (implicated_via_orthology)
Disease	restrictive cardiomyopathy (implicated_via_orthology)	MYH1 MYH4	2.53e-04	13	54	2	DOID:397 (implicated_via_orthology)
Disease	distal arthrogryposis (implicated_via_orthology)	MYH1 MYH4	3.40e-04	15	54	2	DOID:0050646 (implicated_via_orthology)
Disease	Bone marrow hypocellularity	BRCA2 MYSM1	4.94e-04	18	54	2	C1855710
Disease	Adenocarcinoma of prostate	BRCA2 ATM	6.12e-04	20	54	2	C0007112
Disease	BREAST CANCER	BRCA2 ATM	6.75e-04	21	54	2	114480
Disease	Immunologic Deficiency Syndromes	ATM MYSM1	8.11e-04	23	54	2	C0021051
Disease	Pseudoaphakia	ATM AKR1B1	8.84e-04	24	54	2	C0524524
Disease	Lens Opacities	ATM AKR1B1	8.84e-04	24	54	2	C1510497
Disease	memory performance	PDS5B MYH11 UBE4B NT5DC2 HEATR1	9.04e-04	409	54	5	EFO_0004874
Disease	Pancytopenia	BRCA2 MYSM1	1.04e-03	26	54	2	C0030312
Disease	Malignant tumor of breast	BRCA2 ATM	1.12e-03	27	54	2	cv:C0006142
Disease	Breast neoplasm	BRCA2 ATM	1.12e-03	27	54	2	cv:C1458155
Disease	blood manganese measurement	OCRL CLDN10	1.12e-03	27	54	2	EFO_0007581
Disease	Familial cancer of breast	BRCA2 ATM	1.12e-03	27	54	2	cv:C0346153
Disease	Breast Cancer, Familial	BRCA2 ATM	1.38e-03	30	54	2	C0346153

Protein segments in the cluster

Peptide	Gene	Start	Entry
REKAAEVFFETFNVP	ACTR1B	121	P42025
KLNKYQEPDVVNFDF	CNTNAP4	1081	Q9C0A0
TDPFVQEFQFKVRDE	AGO3	391	Q9H9G7
KITTEFFDPLFVEQK	CLDN10	141	P78369
FSQEVFKVTFNPDKE	CFAP44	271	Q96MT7
FKVTFNPDKEEQLTT	CFAP44	276	Q96MT7
TPERIAENFKVFDFE	AKR1B1	266	P15121
QTEFPSKQVFSKEEA	CDCA3	141	Q99618
NFPFDVTKVEVQKFF	RBM12B	406	Q8IXT5
FKTPELAEEFKQKFE	RANBP2	2126	P49792
IFSSKETQFAQIFEP	PDS5B	736	Q9NTI5
KSDFDQTVFQEVFEP	NETO1	376	Q8TDF5
TDFVFQAAVPKTFQL	AP1G1	746	O43747
TEPFVENKAAFKNEA	LYVE1	216	Q9Y5Y7
QDIKFTIKFQEFSPN	EFNB2	106	P52799
FKFNTDAAEFIPQEK	NFX1	11	Q12986
VPQFKKVVFQEFTDG	F8	1746	P00451
EAQNKPFDAKTSVFV	MYH1	26	P12882
VEVTSFAAINKFQPF	MPND	256	Q8N594
TKNFDFEDVFVKIPQ	NDUFA9	136	Q16795
KLIEQFPESFFTIKD	MTERF2	131	Q49AM1
FPESFFTIKDQENQK	MTERF2	136	Q49AM1
TAFNEQVDKFFPLIE	RPA1	236	P27694
FKTPELAEEFKQKFE	RGPD3	1151	A6NKT7
KDFPVNEVFTQFLAD	ATM	1066	Q13315
ESFNKIVNFFDQKPE	BRCA2	1441	P51587
NVALFTEFFEKPDVQ	DNAH17	36	Q9UFH2
VIKNTDSPEFKEQFK	CC2D1A	701	Q6P1N0
EEFPQFPNKVDFIQE	DENND5B	381	Q6ZUT9
FNFFVTAPKNVSDII	ACE2	681	Q9BYF1
VSAFKNQVSKNPFEE	LYST	521	Q99698
FPQEEFDDKQFQKAQ	IFNA8	61	P32881
TKPFFAAISDEKVQQ	HEATR1	1111	Q9H583
VAPEEFVKFQFQRFT	GRIK4	121	Q16099
QQEEFDVFTKAPFSK	BMP2KL	146	Q5H9B9
VTEDNKFFPIQSKDV	PRIMPOL	306	Q96LW4
FKTPELAEEFKQKFE	RGPD4	1151	Q7Z3J3
EKEPKKVFFVDFGNI	TDRD6	1056	O60522
DIIEPKFEFAVKFNA	PPARD	326	Q03181
EKNKSSPIFAFQEEV	SLC46A3	51	Q7Z3Q1
FDPKFAFKEVEVQAK	FTSJ3	211	Q8IY81
FFFKTQEDKEPISEN	SGO2	646	Q562F6
EAQNKPFDAKTSVFV	MYH4	26	Q9Y623
KAFVDFNEGEIKFIP	OCRL	461	Q01968
LQNIKVFDFTFSPEE	AKR1A1	271	P14550
EKFLFVDKNFINSPV	MYH11	11	P35749
FFQKPVTFEDVAVNF	ZFP57	11	Q9NU63
EFTKDFAPVIVEAFK	RPRD1A	76	Q96P16
AQPIFVFEKGEQTFK	RANBP3L	36	Q86VV4
KDFPGEQFFVVFVIK	SIDT1	251	Q9NXL6
QFKQNPKEVFSDFKD	UBE4B	186	O95155
FDSFVVQFKDKDGPQ	TNXB	1701	P22105
FDVVIVQADKPSFFT	NT5DC2	291	Q9H857
NQKFSEEVKTPEFVS	ZNF251	106	Q9BRH9
LKVKDFSEFDFKPQQ	UBE4A	896	Q14139
FSEFDFKPQQLVSDI	UBE4A	901	Q14139
GPTEKFQDKDQVFIF	GTF3C1	981	Q12789
FEKVPESKVIFDANA	TG	1571	P01266
APEEKTQVKTFQAFE	ZFC3H1	286	O60293
KFQDFEVEFSKDHPQ	VPS13D	1646	Q5THJ4
TFSVPNKDVFQELEK	KYNU	406	Q16719
FKFPFTFDEKRAVQQ	MYO5A	666	Q9Y4I1
FFSEEKQEPFQVKVA	MYSM1	566	Q5VVJ2